Prosecution Insights
Last updated: August 18, 2026
Application No. 18/117,966

NOVEL HETEROCYCLIC COMPOUNDS

Final Rejection §102§112
Filed
Mar 06, 2023
Priority
Sep 07, 2020 — CN PCT/CN2020/113771 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
835 granted / 1125 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
75 currently pending
Career history
1178
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1125 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 31 and 36-54 are pending in the instant application. Claims 36-54 are new claims and drawn to the elected species and invention. Claim 31 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 36-54 is contained herein. The full scope of formula I has now been searched. Priority Benefit for the foreign application is accorded for all claims under examination with the exception of claim 54 since subject matter disclosed within the instant application is not supported (e.g. the last two species in claim 19 not being supported). The claims in a U.S. application are entitled to the benefit of a foreign priority date or the filing date of a provisional application if the corresponding foreign application or provisional application supports the claims in the manner required by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph. In re Ziegler, 992 F.2d 1197, 1200, 26 USPQ2d 1600, 1603 (Fed. Cir. 1993); Kawaiv.Metlesics, 480 F.2d 880, 178 USPQ 158 (CCPA 1973); In re Gosteli, 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989). Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 12/17/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 5/4/2026. New Objections and Rejections Claim Objections Claim 54 is objected to for the following: The preamble of the claim should use language such as “wherein the compound is selected from the group consisting of” for proper Markush language. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 36-53 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 36, the limitation wherein variable p is selected from “o” is indefinite. The latter is a letter and it is not clear whether Applicants intend the number “0” or something else. Thus the claim and claims dependent on it which do not rectify the issue are indefinite. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 40, 52, and 54 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 40 and 52 do not further limit claim 36 with respect to variable R8 being selected from “H” since claim 36 does not set this requirement. Claim 54 recites species which do not further limit claim 36 with respect to variable R10: PNG media_image1.png 160 222 media_image1.png Greyscale PNG media_image2.png 172 244 media_image2.png Greyscale These species have the limitation wherein R10 = -C(O)NHalkylamino or R11 = alkylamino which is not supported by claim 36. Applicants are to be aware of all species in the claim which do not further limit claim 36. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 54 is rejected under 35 U.S.C. 102(a)(2) as being anticipated over WO 2023/280733-mentioned in IDS. WO 2023/280733 teaches one of Applicant’s claimed species (see page 125, step 2): PNG media_image3.png 176 310 media_image3.png Greyscale Thus the claim is anticipated. Applicants are to be aware of all species in this document which may potentially anticipate the claim. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Mar 06, 2023
Application Filed
Aug 04, 2023
Response after Non-Final Action
Dec 17, 2025
Non-Final Rejection mailed — §102, §112
Mar 16, 2026
Response Filed
Mar 16, 2026
Response after Non-Final Action
May 04, 2026
Response Filed
Jun 01, 2026
Examiner Interview (Telephonic)
Jun 08, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703694
PYRAZOLE CARBOXYLATE ESTER COMPOUND AND USE THEREOF
3y 11m to grant Granted Aug 11, 2026
Patent 12698283
QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF
3y 7m to grant Granted Aug 04, 2026
Patent 12691129
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
3y 11m to grant Granted Jul 28, 2026
Patent 12673920
INHIBITORS OF NLRP3 INFLAMMASOME
3y 1m to grant Granted Jul 07, 2026
Patent 12667101
PICOLINAMIDE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.4%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1125 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month